Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234834 | 0.90 | GPR119 (0.52) | GPR119GPR183ACACBKCNH2CYP4F2 | |
| SCHEMBL17234760 | 0.90 | GPR119 (0.52) | GPR119GPR183ACACBKCNH2CYP4F2 | |
| SCHEMBL18574991 | 0.90 | GPR119 (0.52) | GPR119GPR183PTPN11DGAT1 | |
| SCHEMBL18843757 | 0.90 | GPR119 (0.46) | GPR119PTPN11DGAT1ACACBAOC3 | |
| SCHEMBL18574856 | 0.89 | GPR119 (0.51) | GPR119GPR183DGAT1KITACACB | |
| SCHEMBL17234761 | 0.89 | GPR119 (0.51) | GPR119GPR183ACACBKCNH2CYP4F2 | |
| Hydrochloric Acid SCHEMBL18574746 | 0.89 | GPR119 (0.51) | GPR119GPR183DGAT1ACACBKCNH2 | |
| SCHEMBL18574958 | 0.89 | GPR119 (0.51) | GPR119GPR183DGAT1KITACACB | |
| Hydrochloric Acid SCHEMBL18574765 | 0.89 | GPR119 (0.51) | GPR119GPR183ACACBKCNH2CYP4F2 | |
| SCHEMBL18843840 | 0.89 | GPR119 (0.45) | GPR119PTPN11DGAT1KITAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| EP-3138834-B1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2018-11-08 | — | — | US | disclosed |
| US-9758527-B2 | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2017-09-12 | — | — | US | disclosed |
| US-9758527-B2 | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2017-09-12 | — | — | US | disclosed |
| WO-2017078352-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-05-11 | — | — | WO | disclosed |
| US-20170114072-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-04-27 | — | — | US | disclosed |
| US-20170114072-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-04-27 | — | — | US | disclosed |
| EP-3138834-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114072-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | GLP1R, GPR119, GCGR | GPR119 2/4885GPR183 19/4885PTPN11 2277/4885 |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | GPR119, GLP1R, GCGR | GPR119 1/4885GPR183 19/4885PTPN11 2815/4885 |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | GPR119, GLP1R, GCGR | GPR119 1/4885GPR183 19/4885PTPN11 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.